Risperidone Long-Acting Injection

Hospital Pharmacy

Volumn 39, Issue 4, 2004, Pages 353-362

  Cada, Dennis J ^a   Levien, Terri ^b   Baker, Danial E ^b,c,d  

^a Formulary   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Drug Information Center   (United States)

^d Department of Pharmacy Practice ^*

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; RISPERIDONE;

AKATHISIA; BODY WEIGHT DISORDER; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; PAIN; PARKINSONISM; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; XEROSTOMIA;

EID: 1842559512     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870403900412     Document Type: Review

References (16)

1. Risperdal Consta (risperidone) long-acting injection [prescribing information]. Janssen; October 2003.
2. Kane JM, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-32.
3. Ramstack M, et al. Long-acting risperidone: Prolonged-release injectable delivery of risperidone using Medisorb microsphere technology [abstract]. Biol Psychiatry. 2003;53:204S.
4. Gefvert O, et al. Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia [abstract]. Biol Psychiatry. 2001;49:117S.
5. Love RC. Strategies for increasing treatment compliance: The role of long-acting antipsychotics. Am J Health Syst Pharm. 2002;59(suppl 8):S10-5.
6. Altamura AC, et al. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs. 2003;63:493-12.
7. Chue P, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets [abstract]. Schizophrenia Res. 2002;53(3, suppl): 174-5.
8. Turner M, et al. Long-acting injectable risperidone: Safety and efficacy in patients switched from conventional depot antipsychotics [abstract]. Schizophrenia Res. 2003;60(1, suppl):305.
9. Eerdekens M, et al. Long-term safety of long-acting risperidone microspheres [abstract]. Schizophrenia Res. 2002;53(3, suppl):174.
10. Chouinard G, et al. Does a long-acting atypical antipsychotic offer a low risk of tardive dyskinesia in patients with schizophrenia [abstract]. Schizophrenia Res. 2003;60(1, suppl):277.
11. Eerdekens M, et al. Long-term safety of long-acting risperidone microspheres [abstract]. Biol Psychiatry. 2002;51:56S.
12. Eerdekens M, et al. Stable elderly patients with psychotic disorders improve with long-acting risperidone [abstract]. Schizophrenia Res. 2003;60(1, suppl):282.
13. Chue P, et al. Hospitalization rates decrease during long-term treatment with long-acting risperidone injection [abstract]. Biol Psychiatry. 2002;12(suppl 3):S281-2.
14. Chue P, et al. One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting intramuscular risperidone [abstract]. Schizophrenia Res. 2003;60(1, suppl):277-8.
15. Nasrallah H, et al. Long-acting, injectable risperidone - the first long-acting, atypical antipsychotic - improves quality of life [abstract]. Biol Psychiatry. 2002;12(suppl 3):S282.
16. Heeg BMS, et al. Costs and effects of Risperdal Consta in comparison to short-acting atypicals and conventional depot formulations in schizophrenic patients at high risk of noncompliance [abstract]. International Society for Pharmacoeconomics and Outcomes Research 5th Annual European Conference; November 3-5, 2002; Rotterdam, The Netherlands. Poster PMH5. www.ispor.org. Accessed November 4, 2003.